English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background  Ceftolozane/tazobactam (C/T), an antipseudomonal cephalosporin combined with a β-lactamase inhibitor, was approved for treatment of complicated urinary tract (cUTI) and intraabdominal infections (cIAI), and hospital-acquired/ventilator-associated bacterial pneumonia (HAP/VAP). Imipenem/relebactam (IMI/REL) is a combination of imipenem/cilastatin with relebactam, an inhibitor of class A and C β-lactamases. IMI/REL was approved for HAP/VAP and for infections due to aerobic gram-negative organisms in adults with limited treatment options (e.g., cUTI, cIAI). We compared the activity of C/T and IMI/REL against  P. aeruginosa  from bloodstream infections (BSI) to those from other infection types.    Methods  As part of the SMART program, 24 hospitals in the US and 8 in Canada each collected up to 250 consecutive gram-negative isolates per year in 2018-2019 from patients with BSI, lower respiratory tract infections (LRTI), IAI, and UTI. A total of 2351  Pa  isolates were collected. MICs were determined using CLSI broth microdilution and breakpoints.    Results    Pa  isolates from BSI tended to show higher susceptibility than IAI, UTI, and especially LRTI isolates (Table). Susceptibility to the tested comparator β-lactams was 11-12 percentage points lower among LRTI than BSI isolates, while C/T and IMI/REL susceptibility was only 2-5% lower. Even among BSI isolates, the comparator β-lactams were active against only 75-88% of isolates, while C/T and IMI/REL were active against >95%. Only amikacin showed higher activity. Analyzing coverage by either C/T or IMI/REL, 98.7% of  Pa  isolates from BSI were susceptible to one or both agents. C/T and IMI/REL maintained activity against 89% and 69% of meropenem-nonsusceptible (MEM-NS)  Pa  isolates from BSI (n=36), respectively, and 87% and 76% of piperacillin/tazobactam (P/T)-NS  Pa  (n=38).  Results TableConclusion  Even among BSI isolates, which were generally more susceptible than those from other infection types,  Pa  susceptibility to commonly used β-lactams like MEM and P/T was < 90%, 7-23% lower than C/T and IMI/REL. Given the desirability of β-lactams among clinicians and the >98% coverage by either C/T or IMI/REL of  Pa  isolates from BSI, both agents represent important options in the treatment of patients with BSI.    Disclosures    Sibylle Lob, PhD ,  IHMA  (Employee) Pfizer, Inc.  (Independent Contractor)  Meredith Hackel, PhD MPH ,  IHMA  (Employee) Pfizer, Inc.  (Independent Contractor)  C. Andrew DeRyke, PharmD ,  Merck & Co., Inc.  (Employee, Shareholder)  Kelly Harris, PharmD, BCPS ,  Merck & Co. Inc  (Employee)  Katherine Young, MS ,  Merck  (Employee)  Mary Motyl, PhD ,  Merck & Co., Inc.  (Employee, Shareholder)  Daniel F. Sahm, PhD ,  IHMA  (Employee) Pfizer, Inc.  (Independent Contractor)

open forum infectious diseases

1274. Activity of Ceftolozane/Tazobactam, Imipenem/Relebactam, and Comparators Against <i>Pseudomonas aeruginosa</i> Isolates from Patients with Bloodstream and Other Infection Types—SMART United States/Canada 2018-2019

1274. Activity of Ceftolozane/Tazobactam, Imipenem/Relebactam, and Comparators Against Pseudomonas aeruginosa Isolates from Patients with Bloodstream and Other Infection Types—SMART United States/Canada 2018-2019